About

Publications While At HealthPartners

selected publications

Journal Article

Glycemic outcomes persist for up to 2 years in very young children with the Omnipod(®) 5 Automated Insulin Delivery System. 

Diabetes Technology & Therapeutics. 2024

Increase access, reduce disparities: recommendations for modifying medicaid CGM coverage eligibility criteria. 

Journal of Diabetes Science and Technology. 2024

Psychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes. 

Diabetes, Obesity & Metabolism. 2024

Two years with a tubeless automated insulin delivery system: a single-arm multicenter trial in children, adolescents, and adults with Type 1 diabetes. 

Diabetes Technology & Therapeutics. 2024

Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. 

Endocrine Reviews. 2023

Improved glycemia with hybrid closed-loop versus continuous subcutaneous insulin infusion therapy: results from a randomized controlled trial. 

Diabetes Technology & Therapeutics. 2023

Safety and glycemic outcomes during the MiniMed(TM) advanced hybrid closed-loop system pivotal trial in children and adolescents with type 1 diabetes. 

Diabetes Technology & Therapeutics. 2023

How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: findings from the first investigation with the Omnipod® 5 System. 

Diabetes Research and Clinical Practice. 2022

Real-world evidence supporting Tandem Control-IQ Hybrid Closed-Loop success in the Medicare and Medicaid type 1 and type 2 diabetes populations. 

Diabetes Technology & Therapeutics. 2022

Safety and glycemic outcomes with a tubeless automated insulin delivery system in very young children with type 1 diabetes: a single-arm multicenter clinical trial. 

Diabetes care. 2022

First outpatient evaluation of a tubeless automated insulin delivery system with customizable glucose targets in children and adults with type 1 diabetes. 

Diabetes Technology & Therapeutics. 2021

Lost in translation: a disconnect between the science and Medicare coverage criteria for continuous subcutaneous insulin infusion. 

Diabetes Technology & Therapeutics. 2021

Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. 

Diabetes care. 2021

Review

Coverage for continuous glucose monitoring for individuals with type 2 diabetes treated with nonintensive therapies: an evidence-based approach to policymaking [review]. 

Diabetes Technology & Therapeutics. 2023

Abstract

First home evaluation of the Omnipod Horizon automated glucose control system at specific glucose targets in children with type 1 diabetes [abstract]. 

Diabetes. 2020

Contact

full name

G. P. Forlenza

Quick Info

 

Collaboration

Co-author network

Map of science